$81.5 Million is the total value of Asymmetry Capital Management, L.P.'s 33 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 71.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTCT | Buy | PTC THERAPEUTICS | $9,200,000 | +29.3% | 551,558 | +55.2% | 12.49% | +51.4% |
| DGX | Buy | QUEST DIAGNOSTICS | $6,265,000 | +75.0% | 63,610 | +66.4% | 8.50% | +104.8% |
| JAZZ | Buy | JAZZ PHARMACEUTICALS | $6,056,000 | -1.6% | 44,976 | +6.9% | 8.22% | +15.1% |
| OPTN | New | OPTINOSE INC | $5,682,000 | – | 300,618 | +100.0% | 7.71% | – |
| INSM | Sell | INSMED INC | $4,935,000 | -25.9% | 158,277 | -25.8% | 6.70% | -13.3% |
| CNC | Sell | CENTENE CORP | $4,642,000 | -31.3% | 46,011 | -34.1% | 6.30% | -19.6% |
| UNH | Sell | UNITEDHEALTH GROUP INC | $4,498,000 | -8.4% | 20,406 | -18.6% | 6.10% | +7.3% |
| BIO | Sell | BIO-RAD LABRATORIES | $3,292,000 | -26.8% | 13,794 | -31.9% | 4.47% | -14.3% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $3,071,000 | -4.4% | 213,413 | +0.2% | 4.17% | +11.9% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $2,410,000 | +175.7% | 40,330 | +124.4% | 3.27% | +222.6% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $2,399,000 | -49.7% | 43,125 | -59.0% | 3.26% | -41.1% |
| NVTA | Sell | INVITAE CORP | $1,968,000 | -28.5% | 216,687 | -26.3% | 2.67% | -16.3% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $1,924,000 | -39.0% | 24,795 | -51.9% | 2.61% | -28.7% |
| NTRA | Sell | NATERA INC | $1,796,000 | -41.2% | 199,777 | -15.7% | 2.44% | -31.2% |
| HRTX | Buy | HERON THERAPEUTICS | $1,795,000 | +76.5% | 99,181 | +57.5% | 2.44% | +106.6% |
| NVRO | Buy | NEVRO CORP | $1,642,000 | +53.0% | 23,785 | +101.5% | 2.23% | +79.2% |
| PRGO | New | PERRIGO CO PLC | $1,580,000 | – | 18,129 | +100.0% | 2.14% | – |
| TEVA | New | TEVA PHARMACEUTICALadr | $1,310,000 | – | 69,124 | +100.0% | 1.78% | – |
| TCMD | Sell | TACTILE SYSTEMS TECHNOLOGY INC | $1,248,000 | -51.4% | 43,089 | -48.1% | 1.69% | -43.1% |
| SGYPQ | Buy | SYNERGY PHARMACEUTICALS INC | $1,065,000 | +35.5% | 477,621 | +76.2% | 1.44% | +58.4% |
| ALDR | Sell | ALDER BIOPHARMACEUTICALS INC | $1,059,000 | -17.8% | 92,518 | -12.1% | 1.44% | -3.9% |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $957,000 | – | 10,733 | +100.0% | 1.30% | – |
| ADMS | New | ADAMAS PHARMACEUTICALS INC | $858,000 | – | 25,311 | +100.0% | 1.16% | – |
| ARRY | New | ARRAY BIOPHARMA INC | $846,000 | – | 66,095 | +100.0% | 1.15% | – |
| DRRX | Sell | DURECT CORPORATION | $810,000 | -48.5% | 878,197 | -1.1% | 1.10% | -39.7% |
| PBYI | New | PUMA BIOTECHNOLOGYINC | $729,000 | – | 7,371 | +100.0% | 0.99% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $539,000 | – | 61,530 | +100.0% | 0.73% | – |
| SNNAQ | Sell | SIENNA BIOPHARMACEUTICALS | $484,000 | -47.7% | 26,692 | -35.9% | 0.66% | -38.8% |
| ECYT | New | ENDOCYTE | $349,000 | – | 81,484 | +100.0% | 0.47% | – |
| KALA | New | KALA PHARMACEUTICALS | $250,000 | – | 13,504 | +100.0% | 0.34% | – |
| PRTO | New | PROTEON THERAPEUTICS INC | $18,000 | – | 9,400 | +100.0% | 0.02% | – |
| CBMX | Exit | COMBIMATRIX CORP | $0 | – | -32,641 | -100.0% | -0.28% | – |
| RGNX | Exit | REGENXBIO INC | $0 | – | -13,448 | -100.0% | -0.51% | – |
| REGN | Exit | REGENERON PHARMACEUTICALS | $0 | – | -2,233 | -100.0% | -1.16% | – |
| TVTY | Exit | TIVITY HEALTH INC | $0 | – | -25,654 | -100.0% | -1.21% | – |
| CLVS | Exit | CLOVIS | $0 | – | -14,008 | -100.0% | -1.34% | – |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -16,295 | -100.0% | -1.47% | – |
| INGN | Exit | INOGEN INC | $0 | – | -14,113 | -100.0% | -1.56% | – |
| JUNO | Exit | JUNO THERAPEUTICS INC | $0 | – | -30,760 | -100.0% | -1.60% | – |
| NITE | Exit | NIGHTSTAR THERAPEUTICS PLCadr | $0 | – | -130,007 | -100.0% | -2.90% | – |
| HMSY | Exit | HMS HOLDING | $0 | – | -141,906 | -100.0% | -3.27% | – |
| IONS | Exit | IONIS PHARMACEUTICALS | $0 | – | -55,965 | -100.0% | -3.29% | – |
| ACHC | Exit | ACADIA HEALTHCARE CO INC | $0 | – | -72,889 | -100.0% | -4.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.